Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute

Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute

MT newswireMT newswire2026/10/23 08:42
04:42 AM EDT, 10/23/2026 (MT Newswires) -- (Updates with Smith & Nephew's response in the fifth paragraph.) Johnson & Johnson's (JNJ) orthopedics business' proposed merger with Smith & Nephew (SNN) has collapsed over a disagreement on who would run the company, the Financial Times reported Friday, citing people familiar with the matter. Smith & Nephew ultimately rejected the deal to create a $34 billion medical technology company unravelled over Johnson & Johnson's plan to install its former Chief Executive Namal Nawana, who left the company in 2019 over a pay dispute, at its helm, the report said. Smith & Nephew wanted to keep current Chief Executive Deepak Nath, the report said. The proposed deal valued the company at around $22 billion, the report said. Smith & Nephew declined to comment. Johnson & Johnson did not immediately reply to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12